FINWIRES · TerminalLIVE
FINWIRES

HKG:1177

11 stories mentioning HKG:1177

Every FINWIRES story that references HKG:1177, newest first.

Asia

Sino Biopharmaceutical Plans HK$2 Billion Stock Buyback

Sino Biopharmaceutical (HKG:1177) has approved a plan to spend up to HK$2 billion over the next 12 months on share repurchases in the open market, according to a filing with the Hong Kong Exchange on Monday.The approved amount may be used for shares repurchased directly by the biotech firm as well as shares acquired by the trustee administering its restricted share award scheme.Since the start of 2026, the company has spent about HK$338 million to acquire 60.35 million shares under its repurchase program.

HKG:1177
Asia

Sino Biopharma Unit Gets Marketing Nod for Licensed Opioid-Induced Constipation Drug in China

Sino Biopharmaceutical (HKG:1177) said Naldemedine obtained marketing approved from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The drug, which has been exclusively licensed by unit Chia Tai Tianqing Pharmaceutical Group, got the approval for the treatment of opioid-induced constipation in adults.

HKG:1177
Asia

Sino Biopharma Unit's Biliary Tract Cancer Drug Gets Priority Review Status in China

Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's TQB3454 tablet was included in the priority review list by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The drug is indicated for the treatment of patients with locally advanced, recurrent and/or metastatic biliary tract cancer harboring IDH1 mutations.

HKG:1177
Asia Markets

Hong Kong Stocks Little Changed as U.S.-Iran Talks Remain Deadlocked; LDROBOT Gains on Debut

Hong Kong stocks were broadly unchanged Monday as diplomatic tensions between the U.S. and Iran remained unresolved.The Hang Seng Index rose 13.13 points to end little changed at 26,406.84, while the Hang Seng China Enterprises Index barely moved in negative territory, slipping 4.87 points to finish at 8,884.20.U.S. President Donald Trump on Sunday rejected Iran's response to a U.S. proposal aimed at ending the conflict, calling Tehran's demands "totally unacceptable."Iran's proposal centered on ending the conflict, lifting sanctions, securing reparations, and gaining recognition of its control over the Strait.Meanwhile, Trump and Chinese President Xi Jinping are expected to discuss Iran, Taiwan, artificial intelligence, and nuclear weapons as the two sides consider extending a critical minerals agreement during their first face-to-face meeting in more than six months.Trump is expected to arrive in Beijing on Wednesday ahead of talks scheduled for Thursday and Friday.In corporate news, Shenzhen LDROBOT (HKG:1236) debuted in Hong Kong, closing nearly 128% higher at HK$60.00, compared with the offer price of HK$26.36.Sino Biopharmaceutical (HKG:1177) advanced over 4% after securing rights to supply GlaxoSmithKline's hepatitis B drug bepirovirsen in China.

Hang SengHKG:1177HKG:1236
Asia

Update: Wuhan YZY Biopharma, Sino Biopharm Unit's Application for Ascites Drug Accepted in China

(Updated to include Wuhan YZY Biopharma, the drug's primary developer)A new drug application for Wuhan YZY Biopharma's (HKG:2496) M701, a drug co-developed by a unit of Sino Biopharmaceutical (HKG:1177), was accepted by China's National Medical Products Administration.The drug was developed for the treatment of malignant ascites caused by advanced epithelial malignancies, according to two separate filings posted with the Hong Kong bourse Thursday.Chia Tai Tianqing Pharmaceutical Group, Sino Biopharmaceutical's unit had, in August 2024, obtained an exclusive sub-licensable license to register, develop, produce, and commercialize the drug in Mainland China.

HKG:1177HKG:2496
Asia

Sino Biopharm Unit's Application for Ascites Drug Accepted in China

Sino Biopharmaceutical (HKG:1177) unit's new drug application for M701 was accepted by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The drug was jointly developed by Chia Tai Tianqing Pharmaceutical Group, a subsidiary of the firm, for the treatment of malignant ascites caused by advanced epithelial malignancies.

HKG:1177
Asia

Sino Biopharmaceutical Enrolls First Patient in Cafelkibart Cancer Drug Trial

Sino Biopharmaceutical (HKG:1177) enrolled the first patient in the phase 3 clinical trial of cafelkibart to treat gastric cancer, the firm said in a Hong Kong bourse filing Thursday.The company will study the medicine's effectiveness in treating gastric cancer or gastroesophageal junction adenocarcinoma as a second-line treatment.Cafelkibart is also known as LM-108 and was developed by the company's LaNova Medicines unit.

HKG:1177
Asia

Sino Biopharmaceutical's Breast Cancer Drug Gets Marketing Nod in China

Sino Biopharmaceutical's (HKG:1177) culmerciclib capsule "CDK2/4/6 inhibitor" in combination with fulvestrant obtained marketing approval from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The approval is for use of the drug for initial endocrine therapy for patients with locally advanced or metastatic breast cancer.This is the second indication of the drug approved for marketing.

HKG:1177
Asia

Sino Biopharmaceutical Appoints Chief Medical Officer

Sino Biopharmaceutical (HKG:1177) appointed Kang Xiaoyan as its chief medical officer, according to a Hong Kong bourse filing Tuesday.Kang has over twenty five years of experience in clinical practice and drug research and development, Sino Biopharmaceutical said.

HKG:1177
Asia

Sino Biopharmaceutical Unit Gets China Nod to Market Cancer Drug

Sino Biopharmaceutical (HKG:1177) said Benmelstobart in combination with Anlotinib obtained marketing approval from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The approval is for the treatment of advanced or unresectable alveolar soft part sarcoma.Benmelstobart and Anlotinib are category 1 innovative drugs developed by Chia Tai Tianqing Pharmaceutical Group, a unit of the company.

HKG:1177
Asia

Sino Biopharmaceutical Unit Enrolls First Patient in Gastric Cancer Drug Trial

Sino Biopharmaceutical (HKG:1177) said unit LaNova Medicines' phase III registrational clinical trial of tecotabart vedotin completed the enrollment of the first patient, according to a Wednesday Hong Kong bourse filing.The study is testing the drug for the first-line treatment of gastric and gastroesophageal junction adenocarcinoma in combination with a PD-1 monoclonal antibody.

HKG:1177